Grant: CIHR Fellowship
Direct Payment
$145,833.00
Title: Defining a common expression signature for leukemic stem cells in acute myeloid leukemia
FY 2009-10
Summary
Cancer stem cells (CSCs) are rare cells capable of initiation and maintenance of malignancy. Most therapeutic strategies tend to target the bulk of the tumor composed of cells that can not initiate malignancy. Hence, the focus of cancer research has shifted to identification and characterization of CSCs in the hope of developing therapies that would specifically target these cells. Leukemic stem cells (LSCs) are among the most well characterized CSCs and initiatives to specifically target these cells, while leaving normal hematopoeitic stem cells (HSCs) unharmed, have already begun. However, it is very difficult to distinguish an HCS from an LSC and thus to develop therapies which specifically target the LSC without harming the normal HSC pool. Therefore, there is great need for identification and the characterization of the differences between HSCs and LSCs. I will utilize two well defined mouse acute myeloid leukemia (AML) models in conjunction with normal HSCs to generate a common gene expression signature for AML LSCs at the single cell level. This expression signature can be further utilized to explore molecular differences between these two cell types. The findings of this project can potentially be applied to human AML samples for prognosis assessment and possibly aid in the development of LSC-specific therapeutic strategies.
Department
Program
CIHR Fellowship
Recipient
Location
Germany
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
203279
Name
Rouhi Arefeh
Country
Germany
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Title: Defining a common expression signature for leukemic stem cells in acute myeloid leukemia
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$145,833
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Acute Myeloid Leukemia; Leukemia; Leukemic Stem Cells; Oncogenes; Trageted Therapy
Abstract
Cancer stem cells (CSCs) are rare cells capable of initiation and maintenance of malignancy. Most therapeutic strategies tend to target the bulk of the tumor composed of cells that can not initiate malignancy. Hence, the focus of cancer research has shifted to identification and characterization of CSCs in the hope of developing therapies that would specifically target these cells. Leukemic stem cells (LSCs) are among the most well characterized CSCs and initiatives to specifically target these cells, while leaving normal hematopoeitic stem cells (HSCs) unharmed, have already begun. However, it is very difficult to distinguish an HCS from an LSC and thus to develop therapies which specifically target the LSC without harming the normal HSC pool. Therefore, there is great need for identification and the characterization of the differences between HSCs and LSCs. I will utilize two well defined mouse acute myeloid leukemia (AML) models in conjunction with normal HSCs to generate a common gene expression signature for AML LSCs at the single cell level. This expression signature can be further utilized to explore molecular differences between these two cell types. The findings of this project can potentially be applied to human AML samples for prognosis assessment and possibly aid in the development of LSC-specific therapeutic strategies.
Competitiondate
201002
Approvedterm2
2 yrs 11 mths
Pinamesdelim
Rouhi, Arefeh
Approvedterm
2 ans 11 mois
Cihrcontribution2
~ $145,833~ $0~